Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NOK needs to do a Stock BuyBack......
Agreed ...just don't give them Access...
Need to tell your Broker your Shares can't be Barrowed by the Shorts...
Need to tell your Broker your Shares can't be Barrowed by the Shorts...
We're glad Gm isn't going to be part owner....Gm Sucks....We just bought more...
Thank you for the Info...i'm back in...
ok Thank you for That....
If passed Nio would 3 yrs to comply....plenty of time to work this out...
When is the House supposed to Vote on Audit report or delist?
https://www.marketwatch.com/story/senate-could-vote-on-bill-that-could-delist-chinese-companies-from-us-stock-exchanges-2020-05-19
The bill would require Chinese companies to establish they are not owned or controlled by a foreign government. Furthermore, they would be required to submit to an audit that can be reviewed by the Public Company Accounting Oversight Board, the nonprofit body that oversees audits of all U.S. companies that seek to raise money in public markets.
Or maybe not....
This is Great News...The Holding Foreign Companies Accountable Act would force Chinese companies to adhere to U.S. securities law.
Nio Congrats Guys and Gals
Thanks for all the news , The races clips are really cool
This is the second consecutive month that Wei Lai has delivered a record number of deliveries, and the monthly delivery volume exceeds 2,000. This will bring about a monthly operating income of about 1 billion yuan to Weilai, which will alleviate the cash flow pressure of Weilai. . Up to now, Weilai has delivered a total of 14,867 units in 2019. Since its delivery in June 2018, the company has delivered a total of 26,215 units.
Please read the Bottom of this article top and bottom of the graph , Google with translate it for you .... http://infos.joyyang.com/cs/201911/14/102916379.html
you may have missed this Resistance level http://prntscr.com/pxidjl
I don't like it at all....
NIO Inc. hired an analyst covering the Chinese electric carmaker as its next chief financial officer, according to people familiar with the matter.
Feng Wei, an auto analyst at China International Capital Corp., will join NIO by as soon as next week, according to the people, who asked not to be identified discussing a private matter. Feng would succeed Louis Hsieh, who resigned late last month citing personal reasons.
NIO declined to comment, as did CICC. Feng didn’t immediately comment.
Feng joined China International Capital Corp in 2013, rising to managing director with a focus on the auto industry including keeping track on NIO. After obtaining Master’s degrees from Tsinghua Univeristy and RWTH Aachen, he went on to work for German auto component maker ZF Friedichshafen AG. and China’s Everbright Securities.
As CFO, Feng will face the challenge of securing funds for NIO secure as the unprofitable carmaker battles an unprecedented slump in Chinese auto sales, including electric vehicles. Backed by technology giant Tencent Holdings Ltd., it sought $200 million from founder William Li and a Tencent affiliate, and plans to spin off some businesses and reduce jobs.
By the end of the third quarter, NIO had cut its workforce to 7,800 from 9,900 employees in January. Having burned through more than $5 billion in four years, it last month failed in an attempt to get local government funding, according to media reports.
China’s EV sales have slumped for four consecutive months, while the overall auto market is down in 16 of the 17 past months. That’s impacting fundraising for EV start-ups in China, according to rival XPeng Motor.
Feng last held a neutral rating on NIO, with a price target of $2.50 a share, or 29% above the stock’s latest closing price, according to data compiled by Bloomberg.
— With assistance by Ying Tian, and Chunying Zhang
NIO Hires China Auto Analyst as Its Next Finance Chief
Bloomberg News
November 13, 2019, 2:35 AM EST Updated on November 13, 2019, 6:26 AM EST
NIO 6.22% rose 6.2% to $1.975 following report Chinese electric vehicle maker Xpeng has raised $400 million in latest funding round, Reuters reported.
Nio Earnings 11/12/19 , we should have a Much Clearer picture....
Pep this is Disgusting..... Aborted Fetal Cells Used As Food Flavor Enhancers
RSS
Comprehensive List Of Companies That Use This Flavor Enhancer
"Public to boycott products of major food companies that are partnering with Senomyx, a biotech company that produces artificial flavor enhancers unless the company stops using aborted fetal cell lines to test their products."
"But when Senomyx ignored their letter, they wrote to the companies Senomyx listed on their website as “collaborators” warning them of public backlash and threatened a boycott. Food giants ,Pepsico, Kraft Foods Campbell Soup, Solae and Nestlé are the primary targets of the boycott, though Senomyx boasts other international partners on their website.
Senomyx - "Using isolated human taste receptors, we created proprietary taste receptor-based assay systems that provide a biochemical or electronic readout when a flavor ingredient interacts with the receptor.”
"Senomyx notes their collaborators provide them with research and development funding plus royalties on sales of products using their flavor ingredients."
“What they do not tell the public is that they are using HEK 293 – human embryonic kidney cells are taken from an electively aborted baby to produce those receptors”...., stated Debi Vinnedge, Executive Director for Children of God for Life, a pro-life watchdog group that has been monitoring the use of aborted fetal material in medical products and cosmetics for years."
“They could have easily chosen COS (monkey) cells, Chinese Hamster Ovary cells, insect cells or other morally obtained human cells expressing the G protein for taste receptors”, Vinnedge added.
AHLC NOTE: Here is where I firmly disagree with these "life" affirming watchdog groups. There is NO "morally" obtainable source for such things. They are being hypocritical because they are missing key information on this topic of using, harvesting sentient life forms for personal gain.
"In writing to their collaborators, it took three letters before Nestlé finally admitted the truth about their relationship with Senomyx, noting the cell line was “well established in scientific research”.
"After hearing Ms. Vinnedge speak publicly on the problem, angry consumers began writing the companies. Both Pepsico and Campbell Soup immediately responded."
“If enough people voice their outrage and intent to boycott these consumer products, it can be highly effective in convincing Senomyx to change their methods”, she noted."
Click here to read the response letters from Pepsico, Campbell Soup and Nestlé letters (Letter 1, 2, 3)
Need proof of Senomyx use of aborted fetal cell lines?
Following is the link to the online article for their patent on sweet receptors (they filed several separate patents for each of the different taste receptors): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC123709/
As it is lengthy and technical, we recommend you simply do a search in the document for HEK-293.
HEK CELL (Human Embryonic Kidney 293 cells), also often referred to as HEK 293, 293 cells, or less precisely as HEK cells are a specific cell line originally derived from human embryonic kidney cells grown in tissue culture. HEK 293 cells are very easy to grow and transfect very readily and have been widely used in cell biology research for many years. They are also used by the biotechnology industry to produce therapeutic proteins and viruses for gene therapy.
Below is a list of products that contain HEK cells.
HEK cell Products; http://www.cogforlife.org/fetalproductsall.pdf
Pepsi Beverages on the Boycott list:
• All Pepsi soft drinks
• Sierra Mist soft drinks
• Mountain Dew soft drinks
• Mug root beer and other soft drinks
• No Fear beverages
• Ocean Spray beverages
• Seattle’s Best Coffee
• Tazo beverages
• AMP Energy beverages
• Aquafina water
• Aquafina flavored beverages
• DoubleShot energy beverages
• Frappuccino beverages
• Lipton tea and other beverages
• Propel beverages
• SoBe beverages
• Gatorade beverages
• Fiesta Miranda beverages
• Tropicana juices and beverages
Score , nice trade....
you should look at the Chart.....
GTBP - Lung cancer cure? news.....
GT BIOPHARMA ANNOUNCES SOLID TUMOR TARGETING TRIKE™ KILLS
Download as PDFOCTOBER 22, 2019
NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR CELLS
TAMPA, Florida, Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity concerning a solid tumor targeting TriKE™ which demonstrates killing of non-small cell lung cancer tumor cells.
According to the American Cancer Society, non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. In 2019, it is estimated there will be 228,150 cases of newly diagnosed lung cancer. Lung cancer is the second most common cancer, and this year it is estimated that 142,670 people will die from lung cancer. The 5-year survival rate for all people with all types of lung cancer is 19%.
Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are excited about the progress Dr. Miller and his colleagues are making developing a TriKE™ which targets solid tumors." Mr. Cataldo further stated "we believe the NSCLC TriKE™ has the potential to offer lung cancer patients with a treatment option that achieves targeted killing of metastatic lung cancer cells in all locations within the body, and hopefully will become part of a scalable and curative therapeutic strategy for lung cancer patients."
About GTB-3550 TriKE™ and GTB-3550 TriKE™ Phase I/II Clinical Trial
GTB-3550 is the Company's first TriKE™ product candidate which is a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The GTB-3550 Phase I/II clinical trial for treatment of patients with CD33-expressing, high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis opened for patient enrollment September 2019. The clinical trial is being conducted at the University of Minnesota's Masonic Cancer Center in Minneapolis, Minnesota under the direction of Dr. Erica Warlick.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE™) and Multi-Target Directed Bispecific Drug Conjugate technology platforms. Our TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize cancer therapies using proprietary TriKE technology developed by researchers at the university to target NK cells to cancer. Our Multi-Target Directed Bispecific Drug Conjugate platform can generate product candidates that are bi-specific, ligand-directed single-chain fusion proteins that, we believe, represent the next generation of targeted therapy.
Forward-Looking Statements
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2018 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.
Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials for GTB-3550 or GTB-1550, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.
We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.
For more information, please visit www.gtbiopharma.com.
Disclosures
TriKE™ is a trademark of GT Biopharma, Inc.
Dr. Miller also serves as Consulting Chief Medical Officer of GT Biopharma, Inc.
For more information, please visit www.gtbiopharma.com
(800) 304-9888
Looks like Profit taking , may pick up more @ 1.50.... Edit just picked some up @ 1.58 saw a trade go through , 400,000 @1.59
I Disagree Tesla has a China Factory Nio builds luxury suv's with Great AI tech and at this price Elon would be a Fool to let this slip by if if even comes to that.....
Probably just have some little detail to work out ,i hope
Nio's stock drops after report that talks of funding for a new factory were halted
Published: Oct 16, 2019 8:17 a.m. ET
0
Author photo
By
TOMI
KILGORE
REPORTER AND EDITOR
Shares of Nio Inc. NIO, +1.31% dropped 5.2% in active premarket trading Wednesday, after a report that talks for a sizable investment to build a factory in China were called off. On Tuesday, the China-based electric car maker's stock rose 1.3% after the National Business Daily (NBD) reported that Nio was in talks with Wuxing District of Huzhou City on funding of over 5 billion renminbi, or about $704 million at current exchange rates, for a factory in the district with a capacity to make 200,000 vehicles a year. On Wednesday, NBD reported the talks were halted given the heavy risks, with no agreement of intent having been reached. Nio's stock has plunged 53.0% over the past three months through Tuesday, while U.S.-based rival EV maker Tesla Inc. shares TSLA, +0.36% have gained 2.2% and the S&P 500 SPX, +1.00% has eased 0.3%.
Nio News... NIO in talks with Huzhou City over 5 billion yuan investment
Chinese electric vehicle maker NIO is in talks with Wuxing District of Huzhou City in east China on a funding of over 5 billion yuan ($707.1 million), and a NIO factory with annual capacity of making 200,000 units will be located in the district as part of the deal.
Tech media 36Kr learned the talk from NIO executives and Huzhou officials. CEO of NIO Li Bin responded to 36Kr that currently the company has nothing much to reveal, but it is in contact with several local governments.
Nice news....
Agreed...
Nio ,Really enjoying this chart action ,test ,bounce and hopefully bust through this morning morning high...
Pcg ,they would be smart to insulate the lines Trim the underbrush dump the gas , problem solved....i do not own this nore do i want to and it sucks for those who have lost ..